Vaccine-induced cytotoxic T lymphocytes protect against retroviral challenge

The development of prophylactic vaccines against retroviral diseases has been impeded by the lack of obvious immune correlates for protection. Cytotoxic T-lymphocyte (CTL), CD4-lymphocyte, chemokine and/or antibody responses have all been associated with protection against HIV and AIDS; however, effective and safe vaccination strategies remain elusive. Here we show that vaccination with a minimal ovine CTL peptide epitope identified within gp51 of the retrovirus bovine leukemia virus (BLV), consistently induced peptide-specific CTLs. Only sheep whose CTLs were also capable of recognizing retrovirus-infected cells were fully protected when challenged with BLV. This retrovirus displays limited sequence variation; thus, in the relative absence of confounding CTL escape variants, virus-specific CTLs targeting a single epitope were able to prevent the establishment of a latent retroviral infection.

[1]  A. Burny,et al.  Experimental transmission of enzootic bovine leukosis to sheep: latency period of the tumoral disease. , 1988, Leukemia.

[2]  E. Rosenberg,et al.  Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. , 1997, Science.

[3]  N. Letvin,et al.  A vaccine-elicited, single viral epitope-specific cytotoxic T lymphocyte response does not protect against intravenous, cell-free simian immunodeficiency virus challenge , 1995, Journal of virology.

[4]  J. Lloyd,et al.  Depletion of IFN‐γ, CD8+ or Tcrγδ+ cells in vivo during primary infection with an enteric parasite (Trichostrongylus colubriformis) enhances protective immunity , 1995 .

[5]  D. Burton A vaccine for HIV type 1: the antibody perspective. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[6]  D. Moss,et al.  Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination. , 1998, Journal of immunology.

[7]  G. de Thé,et al.  An HTLV-I/II vaccine: from animal models to clinical trials? , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[8]  Hassan Mohammad Naif,et al.  Molecular cloning and sequencing of an Australian isolate of proviral bovine leukaemia virus DNA: comparison with other isolates. , 1990, The Journal of general virology.

[9]  Hassan Mohammad Naif,et al.  Protection of sheep against bovine leukemia virus (BLV) infection by vaccination with recombinant vaccinia viruses expressing BLV envelope glycoproteins: correlation of protection with CD4 T-cell response to gp51 peptide 51-70 , 1993, Journal of virology.

[10]  S. Rowland-Jones,et al.  Role of cellular immunity in protection against HIV infection. , 1997, Advances in immunology.

[11]  Dennis R. Burton,et al.  Why do we not have an HIV vaccine and how can we make one? , 1998, Nature Medicine.

[12]  B. Coupar,et al.  Antigen specificity of the ovine cytotoxic T lymphocyte response to bluetongue virus. , 1995, Veterinary immunology and immunopathology.

[13]  S. Kent,et al.  Detection of simian immunodeficiency virus (SIV)-specific CD8+ T cells in macaques protected from SIV challenge by prior SIV subunit vaccination , 1996, Journal of virology.

[14]  B. Walker,et al.  HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes , 1998, Nature.

[15]  J. Guillet,et al.  Selection of Virus Variants and Emergence of Virus Escape Mutants after Immunization with an Epitope Vaccine , 1998, Journal of Virology.

[16]  A. McMichael,et al.  Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques , 1995, Nature Genetics.

[17]  D. Moss,et al.  Induction of protective cytotoxic T cells to murine cytomegalovirus by using a nonapeptide and a human-compatible adjuvant (Montanide ISA 720) , 1995, Journal of virology.